Novo Nordisk AS (OCSE:NOVO B) EPS (Basic): kr27.45 (TTM As of Mar. 2026)


OCSE:NOVO B Novo Nordisk AS OCSE:NOVO B
84 GF Score
Price kr307.75
GF Value kr907.05
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS EPS (Basic)?

Novo Nordisk AS OCSE:NOVO B +2.60% 84 EPS (Basic) is kr27.45 as of Mar. 2026. GuruFocus rates OCSE:NOVO B with a GF Score™ of 84/100 and a GF Value™ of kr907.05 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Novo Nordisk AS's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was kr10.93. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was kr27.45.

Novo Nordisk AS's EPS (Diluted) for the three months ended in Mar. 2026 was kr10.91. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr27.41.

Novo Nordisk AS's EPS without NRI for the three months ended in Mar. 2026 was kr6.63. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 23.13.

During the past 12 months, Novo Nordisk AS's average EPS without NRIGrowth Rate was -1.50% per year. During the past 3 years, the average EPS without NRI Growth Rate was 25.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 25.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 13.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Novo Nordisk AS's highest 3-Year average EPS without NRI Growth Rate was 38.20% per year. The lowest was -2.90% per year. And the median was 18.80% per year.

Novo Nordisk AS  (OCSE:NOVO B) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Novo Nordisk AS EPS (Basic) Related Terms

Novo Nordisk AS EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Novo Nordisk AS's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS EPS (Basic) Chart

Novo Nordisk AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.40 12.26 18.67 22.67 23.06

Novo Nordisk AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.54 5.96 4.50 6.06 10.93
OCSE:NOVO B
84GF Score
Novo Nordisk AS OCSE:NOVO B
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Nordisk AS EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Novo Nordisk AS's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(102434-0)/4443.000
=23.06

Novo Nordisk AS's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(48557-0)/4442.543
=10.93

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr27.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of kr27.45 mean?
Novo Nordisk AS (OCSE:NOVO B) has a EPS (Basic) of kr27.45 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's EPS (Basic) too high?
Novo Nordisk AS's current EPS (Basic) is kr27.45. Overall, Novo Nordisk AS has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's EPS (Basic) compare to LLY and JNJ?
Novo Nordisk AS's EPS (Basic) of kr27.45 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Novo Nordisk AS and its competitors. Novo Nordisk AS's current EPS (Basic) is kr27.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (OCSE:NOVO B) is currently considered Significantly Undervalued. The stock's GF Value™ is kr907.05, compared to a current price of kr307.75 — trading 66.1% below its estimated fair value. The current EPS (Basic) is kr27.45. Novo Nordisk AS's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Novo Nordisk AS (OCSE:NOVO B), the current EPS (Basic) is kr27.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novo Nordisk AS (OCSE:NOVO B) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of kr307.75 is trading 66.1% below its estimated GF Value™ of kr907.05. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for OCSE:NOVO B:

  • EPS (Basic): kr27.45
  • GF Value™: kr907.05 vs. price of kr307.75 (66.1% below fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the OCSE:NOVO B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
84GF Score

Get the complete analysis for OCSE:NOVO B

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr307.75
Price
kr907.05
GF Value